Eighth Circuit Upholds PBM Express Scripts’ Contractual Termination Rights and Rejects Antitrust Claims in Irmat v. Express Scripts

Introduction

The case of Park Irmat Drug Corp. v. Express Scripts Holding Company (911 F.3d 505) adjudicated by the United States Court of Appeals for the Eighth Circuit on December 12, 2018, revolves around contractual disputes and antitrust allegations filed by Park Irmat Drug Corporation (“Irmat”) against Express Scripts Holding Company and Express Scripts, Inc. (“Express Scripts”). Irmat, an independent pharmacy specializing in dermatological pharmaceuticals and operating both retail and mail-order services, sought to challenge Express Scripts' termination from its pharmacy benefits manager (PBM) network, alleging contractual breaches and violations of federal antitrust laws as well as state Any Willing Provider laws.

Summary of the Judgment

The district court dismissed Irmat's complaint for failure to state a claim, a decision which Express Scripts appealed. The Eighth Circuit Court affirmed the dismissal, holding that Irmat failed to provide sufficient factual allegations to substantiate claims of unconscionability, breach of the covenant of good faith and fair dealing, and violations of the Sherman Act. The court determined that the contractual terms allowing Express Scripts to terminate the agreement without cause were enforceable and that Irmat's antitrust claims lacked the necessary factual support to proceed.

Analysis

Precedents Cited

The judgment extensively references several key precedents that guided the court's decision:

  • Christiansen v. W. Branch Community School District, 674 F.3d 927 (8th Cir. 2012) – Emphasized the necessity of plausibility in complaints to survive a motion to dismiss.
  • McShane Construction Co. v. Gotham Insurance Co., 867 F.3d 923 (8th Cir. 2017) – Clarified the standard for evaluating facial plausibility in claims.
  • Bell Atlantic Corp. v. Twombly, 550 U.S. 544 (2007) – Established the requirement for a claim under the Sherman Act to show more than parallel conduct and suggestive conspiracy.
  • BJC Health System v. Columbia Casualty Co., 478 F.3d 908 (8th Cir. 2007) – Discussed bad faith in the context of contract termination.
  • MARTIN v. AMERICAN FAMILY MUTUAL INSURANCE Co., 157 F.3d 580 (8th Cir. 1998) – Addressed the limitations of the covenant of good faith and fair dealing in contract termination scenarios.

These precedents collectively underscored the necessity for plaintiffs to present clear, specific, and plausible allegations to substantiate claims, especially in complex areas such as contract law and antitrust regulations.

Legal Reasoning

The court's legal reasoning centered on evaluating the sufficiency of Irmat's claims under both contract and antitrust law frameworks.

  • Contractual Claims:
    • Unconscionability: The court found that unilateral termination clauses are permissible in bilateral contracts unless they are exercised in an unrestricted manner. Irmat failed to demonstrate that the contract was a contract of adhesion or that Express Scripts exerted undue pressure, especially given Irmat's access to over 100 PBM networks.
    • Covenant of Good Faith and Fair Dealing: The court held that Express Scripts acted within its contractual rights, as the termination was executed in accordance with the agreement terms, negating any breach of the covenant.
    • Promissory Estoppel: Irmat could not establish that Express Scripts made a definitive promise that would prevent termination, especially since the contract allowed for termination without cause.
    • Novation: The August 2015 email from Express Scripts was deemed part of the recredentialing process and lacked the essential elements of a new contract, thereby not constituting a novation.
  • Antitrust Claims:
    • Sherman Act Section 1: Irmat's allegations of conspiracy and parallel conduct between Express Scripts and CVS Health were dismissed due to the lack of temporal proximity and evidence of coordinated action.
    • Sherman Act Section 2: The failure to define an appropriate relevant market rendered Irmat's monopoly claims insufficient. Additionally, no anticompetitive conduct by Express Scripts was substantiated.
    • Tying Arrangement: Irmat's claim that Express Scripts engaged in a tying arrangement was dismissed as the alleged conditions were seen as anticompetitive conduct repackaged under the guise of a market competition argument.
  • State Any Willing Provider Laws: The court declined to extend the application of Georgia, Mississippi, and North Carolina's Any Willing Provider laws to PBMs, citing the lack of relevant case law and the appropriateness of leaving such extensions to future cases.

Overall, the court meticulously analyzed each claim, applying established legal standards to determine the merits of Irmat's allegations, ultimately finding them unpersuasive and insufficient to warrant a reversal of the district court's dismissal.

Impact

This judgment reaffirms the enforceability of unilateral termination clauses within PBM contracts, particularly for entities holding significant market power like Express Scripts. It clarifies that:

  • PBMs can lawfully include termination clauses allowing exit without cause, provided they adhere to the stipulated notice requirements.
  • Antitrust claims against PBMs require substantial evidence of coordinated anticompetitive behavior, beyond mere parallel actions or competitive dominance.
  • State-specific Any Willing Provider laws are not automatically applicable to PBMs, reserving any such extensions for future judicial consideration.

For independent pharmacies and other entities engaging with PBMs, this decision underscores the importance of carefully negotiating and understanding contract terms, especially regarding termination rights. Additionally, it signals that antitrust challenges against dominant PBMs will necessitate robust evidence demonstrating explicit anticompetitive agreements or conduct.

Complex Concepts Simplified

Pharmacy Benefits Managers (PBMs)

PBMs like Express Scripts act as intermediaries between pharmacies, pharmaceutical companies, and health insurance providers. They manage prescription drug benefits, negotiate prices, process claims, and create pharmacy networks. Their role significantly influences drug pricing and pharmacy practices.

Unconscionability in Contracts

A contract is deemed unconscionable if it is excessively one-sided, thereby oppressing or unfairly surprising one party. Unconscionability can be procedural (issues with how the contract was formed) or substantive (issues with the terms themselves).

Covenant of Good Faith and Fair Dealing

This is an implied term in all contracts, ensuring that neither party will do anything to adversely affect the rights of the other to receive the benefits of the agreement. A breach occurs if one party undermines the contract's spirit or prevents the other from receiving its intended benefits.

Promissory Estoppel

Promissory estoppel allows a party to recover on a promise even in the absence of a formal contract, provided there was a clear and definite promise, reliance on that promise, and resulting injustice if the promise is not enforced.

Section 1 and Section 2 of the Sherman Act

Section 1 prohibits contracts, combinations, or conspiracies that restrain trade or commerce. This includes explicit agreements to fix prices or divide markets. Section 2 addresses the issue of monopolization, making it illegal to monopolize or attempt to monopolize any part of trade or commerce. Establishing a violation requires demonstrating both monopoly power and anticompetitive conduct.

Tying Arrangements

A tying arrangement occurs when a company requires buyers to purchase a secondary product or service as a condition of buying a primary product. This practice can be anticompetitive if it leverages market power to restrict competition in the tied product's market.

Novation

Novation is the process of substituting a new contract in place of an old one, requiring the consent of all parties involved. It extinguishes the original obligations and replaces them with new ones.

Conclusion

The Eighth Circuit’s affirmation in Park Irmat Drug Corp. v. Express Scripts Holding Company underscores the judiciary's stance on upholding contractual provisions favoring termination without cause, especially within dominant PBM networks. The dismissal of antitrust claims highlights the stringent evidentiary standards required to challenge monopolistic practices and anticompetitive behaviors under the Sherman Act. This decision serves as a pivotal reference for future disputes involving PBMs, independent pharmacies, and the intricate balance between contractual freedom and competitive law. Parties engaging in such contracts must meticulously negotiate terms and remain cognizant of the legal boundaries delineated by this and similar judgments.